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Abstract
Total pancreatectomy with islet autotransplantation (TPIAT) is being used increasingly as a 
definitive treatment for chronic pancreatitis. Patients with chronic pancreatitis have an elevated 
risk of pancreatic cancer, which can also masquerade as acute or chronic pancreatitis, making the 
diagnosis challenging. We describe here the first case of pancreatic ductal adenocarcinoma 
developing in the liver of a patient after TPIAT for presumed benign chronic pancreatitis. 
Retrospective analysis of the patient’s preoperative serum revealed normal carbohydrate antigen 
19-9 and carcinoembryonic antigen levels but elevated levels of microRNAs -10b, -30c, and -106b 
compared with controls. Screening guidelines are important to reduce the risk of transplantation of 
malignant tissue. More sensitive screening tools, including the potential use of microRNAs, are 
needed to detect early preclinical disease, given the highly malignant nature of pancreatic cancer.
Introduction
Chronic pancreatitis is characterized pathologically by progressive destruction of pancreatic 
parenchyma and marked fibrosis. Clinically, it is marked by varying degrees of potentially 
debilitating pain, exocrine insufficiency, and endocrine dysfunction that can lead to 
pancreatogenic diabetes. In addition to the ramifications of these chronic conditions, patients 
with chronic pancreatitis are at an increased risk of pancreatic cancer. Therapies to relieve 
pain may include endoscopic and surgical attempts to relieve pressure in the pancreatic duct 
and parenchyma. Unfortunately, subsets of patients are not responsive to or appropriate for 
drainage procedures, limited resection, or other nonsurgical treatment modalities.
Total pancreatectomy with islet autotransplantation (TPIAT) is a treatment that is 
increasingly being used for patients with refractory disease. Because removal of the entire 
pancreas leads to complete insulin deficiency, the process of islet autotransplantation was 
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developed (1). Classically, the processed islets are infused into the portal venous system with 
subsequent embolization into the liver for engraftment.
More than 1000 cases of TPIAT for benign chronic pancreatitis have been performed to date, 
with no reports of iatrogenic pancreatic cancer metastasis (2–9). In this paper, we report the 
first case of pancreatic ductal adenocarcinoma (PDAC) developing in the liver of a patient 
several months after undergoing TPIAT for chronic pancreatitis. Retrospective evaluation of 
the patient’s serum prior to pancreatectomy revealed the presence of elevated levels of three 
distinct microRNAs (miRNAs) known to be elevated in the plasma of patients with PDAC 
but not chronic pancreatitis, suggesting that this patient had early PDAC that was not 
detected by conventional cancer screening or markers.
Case Report
A 43-year-old male presented to the clinic with 5 years of abdominal pain secondary to 
chronic pancreatitis. He developed his first episode of acute pancreatitis in 2009 and 
required intensive care unit admission. This led to escalating episodic pain over several years 
that required multiple hospitalizations for pancreatitis. He began pancreatic enzyme therapy 
and underwent cholecystectomy and multiple endoscopic retrograde 
cholangiopancreatographies with more than five stents placed, all resulting in limited relief. 
At this point, he presented to the clinic for definitive therapy, given the failure of medical 
and endoscopic therapy to control his progressively worsening pancreatitis symptoms and 
significant debilitation from chronic pain. His medical history was otherwise unremarkable 
with pertinent endoscopic and surgical procedures, as listed above. He used a buprenorphine 
patch, tramadol, oxycodone and hydromorphone for pain relief. He reported tobacco 
smoking with a history of 13 pack-years but denied alcohol use since his first pancreatitis 
episode. His family history was negative for chronic pancreatitis or pancreatic malignancies.
His clinical examination was remarkable for epigastric tenderness. Preoperative laboratory 
test results were notable for elevated lipase (401 U/L); normal endocrine function (fasting 
glucose 73 mg/dL, stimulated C-peptide maximum 5.1 ng/mL, hemoglobin A1c [HgA1c] 
4.9%, insulin antibodies <0.4); and normal liver, hematologic and coagulation profiles.
Computed tomography (CT) scan at the time of initial surgical evaluation (Figure 1A) 
demonstrated acute necrotizing pancreatitis in the setting of chronic pancreatitis with lack of 
enhancement in the body, along with pancreatic and peripancreatic necrotic collections. 
Magnetic resonance imaging (MRI) revealed mild dilation and irregularity of the main 
pancreatic duct and side branches, with no masses or strictures. Findings were consistent 
with chronic pancreatitis, more marked in the tail than the head. Endoscopic 
ultrasonography (EUS) revealed four of nine Rosemont criteria (10) for chronic pancreatitis 
with no masses identified.
A multidisciplinary team (gastroenterologist, surgeon, endocrinologist, pain specialist, 
psychologist, and dietician) evaluated the patient, and he met institutional criteria, as 
published previously (2), for consideration for TPIAT without evidence of malignancy or 
other contraindications. He underwent TPIAT with splenectomy, appendectomy, feeding 
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jejunostomy, and gastrostomy tube placement. Sections of pancreas, duodenum, spleen, 
appendix, and omentum were sent to pathology for evaluation (Figure 1B). The patient 
received an infusion of 2116 islet equivalents per kilogram into the portal venous system. 
The patient tolerated the procedure well, had an unremarkable hospital course, and was 
discharged from the hospital on postoperative day (POD) 10. At follow-up 3 mo after 
surgery, he had discontinued all narcotics, required 7 units of insulin glargine daily and 
small amounts of mealtime corrections. Laboratory tests reflected normal endocrine function 
(stimulated C-peptide maximum 1.4 ng/mL, HgA1c 5.5%).
Approximately 10 mo after surgery, the patient developed right upper quadrant pain, low-
grade fevers, and malaise. Subsequent CT and MRI demonstrated several new necrotic liver 
lesions (Figure 1C). Ultrasound-guided core needle biopsy revealed liver parenchyma 
infiltrated by malignant epithelial cells (Figure 1D). The patient underwent two cycles of 
chemotherapy with gemcitabine and one cycle with gemcitabine and abraxane but ultimately 
died from his illness.
Methods
The University of Minnesota institutional review board (IRB) reviewed and approved the 
prospective study of patients undergoing TPIAT.
Clinical specimens
At the time of TPIAT, the surgically resected pancreas was processed with intact C1 
collagenase (Vitacyte, Indianapolis, IN) and neutral protease (SERVA Electrophoresis, 
Heidelberg, Germany) in the islet-processing laboratory, as described previously (2). A 
volume of 15 cm3 of tissue, with a purity of 15% islets, was recovered from 116.5 g of the 
original resected pancreas, indicating 87.1% reduction of tissue volume during the isolation 
procedure. Tissue volume was appropriate for transfusion; therefore, it did not require 
purification based on our standard criteria (11). Nonprocessed pancreatic neck samples were 
sent to pathology, fixed in formalin and embedded in paraffin. Liver biopsies were 
performed with radiographic guidance 11 mo after surgery, fixed in formalin, and embedded 
in paraffin. The tissue samples were stained with hematoxylin and eosin. A battery of 
immunostaining of the liver tissue was performed, as described in the next section. Serum 
samples were saved as part of an ongoing prospective IRB approved study of TPIAT 
outcomes.
Analysis of miRNA
Assays for miRNAs -10b, -30c, and -106b were performed retrospectively. Serum samples 
were taken prior to surgery and on postoperative days 1 and 3. Samples were stored at 
−80°C prior to analysis. Assays were also performed on serum taken from four chronic 
pancreatitis patients at these same time points who underwent TPIAT and who have no 
evidence of pancreatic adenocarcinoma to date. To measure miRNA levels, total RNA was 
isolated from serum samples using Trizol-LS reagent (Life Technologies, Carlsbad, CA). 
RNA was then converted to cDNA for each TaqMan Gene Expression Assay target 
(miR-10b, -30c, and -106b) and the reference assay (miR-425-5p) using the TaqMan 
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MicroRNA Reverse Transcription Kit (Applied Biosystems). Assay-specific cDNA was then 
added to a master mix containing the assay-specific probe and TaqMan Fast Advanced 
Master Mix (Applied Biosystems), according to the manufacturer’s protocol, as previously 
reported (12). Quantitative real-time PCR (qRT-PCR) was performed with the ViiA7 system 
(Applied Biosystems) and ΔCT values for each miRNA were determined by subtracting the 
reference assay CT value from the target assay CT value. To calculate the ΔΔCT values, an 
average of the ΔCT for each miRNA of six normal control serum samples was used, and fold 
changes were determined as 2-ΔΔCT (13).
Results
Histology
Pancreas pathology from the index operation demonstrated pancreatic tissue with severe 
chronic pancreatitis as well as pancreatic intraepithelial neoplasia II (Figure 1B). Ampullary 
mucosa demonstrated acute inflammation and squamous metaplasia. One lymph node was 
extracted and was negative for malignancy. The pancreas, spleen, duodenum, appendix and 
omentum were also found to have no evidence of carcinoma.
Microscopic examination of the liver biopsies taken 11 mo after TPIAT demonstrated liver 
parenchyma infiltrated by malignant epithelial cells forming glands consistent with 
metastatic moderately differentiated adenocarcinoma. The malignant cells were reactive to 
cytokeratin 7, cytokeratin 20 and carbohydrate antigen (CA) 19-9. There were no reactions 
with antibodies to caudal type homeobox 2, prostate-specific antigen, prostate-specific acid 
phosphatase or thyroid transcription V1. A reticulin stain did not highlight a pattern of 
expansion or collapse or individual cell necrosis in the areas of uninvolved liver 
parenchyma. Masson’s trichrome stain demonstrated increased portal fibrosis in areas of 
uninvolved liver parenchyma.
Tumor markers
Retrospective analysis of the patient’s stored serum revealed normal preoperative tumor 
markers: CA 19-9 of 7 U/mL and carcinoembryonic antigen (CEA) <0.5 μg/L. At the time 
of pain recurrence 11 mo postoperatively, his levels had risen significantly to CA 19-9 of 39 
872 U/mL and CEA 92.3 μg/L.
Plasma miRNA levels
Stored serum samples from the chronic pancreatitis patient who developed PDAC (chronic 
pancreatitis– PDAC) and four patients with chronic pancreatitis also treated with TPIAT 
were assayed retrospectively for miRNAs -10b, -30c and -106b. The chronic pancreatitis–
PDAC patient’s preoperative serum levels were ≈20-fold, five-fold, and sevenfold higher, 
respectively, than in the corresponding chronic pancreatitis cases. Moreover, the elevated 
serum levels of all three microRNAs decreased rapidly following pancreas resection in the 
chronic pancreatitis– PDAC patient, whereas the normal levels in the four chronic 
pancreatitis patients did not change after resection (Table 1).
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Discussion
This report is the first of hepatic PDAC metastases after TPIAT for chronic pancreatitis. In 
this case, the patient had no radiographic evidence of malignancy prior to undergoing 
TPIAT, and retrospective analysis of his preoperative serum revealed normal CA 19-9 and 
CEA levels. Given the increasing use of TPIAT in the treatment armamentarium for chronic 
pancreatitis, it is important to establish guidelines for preoperative screening and to develop 
additional tools to help identify patients at increased PDAC risk.
With 5-year survival rates of approximately 7%, PDAC remains the fourth leading cause of 
death from cancer in the United States. In contrast to decreasing mortality trends for breast 
and colon cancer, yearly incidence and mortality for pancreatic cancer continue to rise (14). 
PDAC is projected to become the second leading cause of cancer deaths in adults within a 
decade (15). Advancing age, smoking, obesity, long-standing type 2 diabetes and family 
history are established risk factors for developing PDAC (16,17). In addition, several 
familial cancer syndromes, such as Li–Fraumeni syndrome, BRCA2, hereditary 
nonpolyposis colon cancer, and Peutz–Jeghers syndrome, have also been shown to confer 
varying degrees of increased risk of developing PDAC (18).
Numerous case–control, cohort, and record-linkage studies have demonstrated that chronic 
pancreatitis also confers an increased risk of developing PDAC, although reported risk rates 
vary across studies (16). Patients with inherited chronic pancreatitis have the highest risk of 
PDAC development. In a European study, researchers demonstrated that the risk of PDAC in 
hereditary chronic pancreatitis patients was about 50 times higher than in the corresponding 
population, with a 44% cumulative risk of PDAC by age 70 years (19). It has also been 
shown that patients with hereditary pancreatitis and current or former smoker status have a 
twofold increased risk of pancreatic cancer and develop cancer on average 20 years earlier 
compared with nonsmokers (20).
The U.S. Preventive Services Task Force does not currently recommend routine screening 
for PDAC in asymptomatic persons (21). This recommendation is based in part on the 
absence of sensitive and specific tests for early PDAC diagnosis. Case reports or limited 
series of TPIAT in the setting of known malignancy have been reported (22–24); however, 
this is not currently recommended in the United States, given the risk of iatrogenic 
metastasis of PDAC, as demonstrated in this report. Although the majority of exocrine tissue 
is enzymatically separated from the islet cells in preparation for transplantation, and the 
remaining nonendocrine tissue does not survive the initial 2-week engraftment period, this 
case demonstrates that malignant cells can survive enzymatic digestion and embolize to the 
liver during autotransfusion into the portal venous system, resulting in metastatic pancreatic 
cancer. This underscores why the noted risk factors for PDAC should be taken into 
consideration during preoperative screening of patients being evaluated for TPIAT.
Because of the risk for preexisting subclinical malignancy in chronic pancreatitis patients, 
we developed a sequential algorithm for preoperative evaluation to selectively increase 
pancreatic cancer screening in high-risk persons (Figure 2). This scheme recognizes that CT 
or MRI will identify the majority of patients with large duct or calcific disease. Additional 
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screening with EUS or tumor markers for high-risk patients should be used as indicated. 
Recent studies have explored the utilization of miRNAs as potential biomarkers for PDAC 
(25). These small nonprotein coding RNAs are involved in biological processes such as cell 
proliferation, differentiation, migration, invasion, and survival and have been implicated in 
the pathogenesis of numerous cancers through both up- and downregulation (25). A previous 
study demonstrated that levels of miRNA-10b, -30c, -155 and -106b were elevated in the 
plasma of patients with PDAC by comparison with chronic pancreatitis patients and healthy 
controls (25); however, miR-155 is expressed in the CD45+ T cells in PDAC and not in the 
pancreatic cancer cells (26). Consequently, retrospective analysis of stored serum samples 
were performed in this case and detected elevated miRNA -10b, -30c, and -106b levels in the 
chronic pancreatitis– PDAC patient in comparison to the four chronic pancreatitis patients 
also undergoing TPIAT. Clearly, neither CA 19-9 nor CEA are good markers for early PDAC 
diagnosis and would have failed to raise suspicion for malignancy in this case. In contrast, 
the inclusion of miRNA -10b, -30c, and -106b testing may provide a unique tool at this point 
in care for identification of patients with early preclinical PDAC not identified by 
conventional tumor markers.
Conclusion
TPIAT has been performed worldwide in >1000 patients since 1977, and this report is the 
first of a case of autotransplantation of pancreatic malignancy after TPIAT for presumed 
benign chronic pancreatitis; malignancy was undetectable prior to surgery with conventional 
tumor markers or imaging. For patients at an increased risk of pancreatic cancer, additional 
screening may be indicated. Preoperative assays for miRNAs -10b, -30c, and -106b are 
potentially sensitive screening techniques; however, further study is needed. This case report 
points to the need for studies of larger populations of such patients and underscores the need 
to avoid TPIAT in the setting of known pancreatic cancer.
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CA carbohydrate antigen
CEA carcinoembryonic antigen
CP chronic pancreatitis
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HgA1c hemoglobin A1c
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MRI magnetic resonance imaging
PDAC pancreatic ductal adenocarcinoma
POD postoperative day
TPIAT total pancreatectomy with islet autotransplantation
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Figure 1. 
Imaging and microscopic examination of tissue before (A and B) and 11 mo after (C and D) 
total pancreatectomy with islet autotransplantation. (A) Cross-sectional image from a 
pancreas protocol computed tomography (CT) scan with intravenous contrast obtained at 
time of initial surgical evaluation, demonstrating acute necrotizing pancreatitis in the setting 
of chronic pancreatitis with pancreatic and peripancreatic necrotic collections as well as a 
pancreatic duct stent. (B) Microscopic examination of hematoxylin and eosin–stained 
pancreas tissue at the time of total pancreatectomy with islet autotransplantation, 
demonstrating chronic pancreatitis and pancreatic intraepithelial neoplasia II. (C) Follow-up 
CT at 1 year after surgery, demonstrating low-density liver lesions with ill-defined borders, 
the largest of which measured 10 cm in diameter. (D) Microscopic examination of 
hematoxylin and eosin–stained biopsy of liver lesion, consistent with metastatic pancreatic 
adenocarcinoma.
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Figure 2. TPIAT preoperative screening algorithm for patients with chronic pancreatitis or 
recurrent acute pancreatitis
*Complete blood count, basic metabolic panel, liver function tests, amylase, lipase, 
endocrine function, coagulation profile, CT/MRI, EUS. †Patients with hereditary 
pancreatitis, family history of pancreatic cancer or familial cancer syndromes revert to 
respective pathway above. **Consider additional biomarker screening. CA, carbohydrate 
antigen; CEA, carcinoembryonic antigen; CT, computed tomography; EUS, endoscopic 
ultrasound; MRI, magnetic resonance imaging; TPIAT, total pancreatectomy with islet 
autotransplantation.
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